2025
Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer (aBC).
Bou Farhat E, Nassar A, Abushukair H, Alchoueiry M, Salem S, Machaalani M, Henske E, Choueiri T, Rakaee M, Adib E, Naqash A, Jansen C, Wang X, Challa P, Rodig S, Tarantino P, Partridge A, Tolaney S, Winer E, Kwiatkowski D. Molecular and clinical insights of trastuzumab deruxtecan efficacy in advanced breast cancer (aBC). Journal Of Clinical Oncology 2025, 43: 1040-1040. DOI: 10.1200/jco.2025.43.16_suppl.1040.Peer-Reviewed Original ResearchTime to next treatmentAdvanced breast cancerTumor micro-environmentT-DXdHER2-lowOverall survivalHER2 statusERBB2 amplificationHER2-0Shorter time to next treatmentPTEN-mutatedFirst-line systemic therapyMultivariate Cox proportional hazards modelHER2 3+Cox proportional hazards modelsRefine treatment strategiesPredictive of outcomeTargeted tumor sequencingProportional hazards modelImpact of molecular markersHER2 3Trastuzumab deruxtecanHER2-positiveHER2 immunohistochemistrySystemic therapyLeveraging space innovations for cancer breakthroughs on Earth
Akbarialiabad H, Jamshidi P, Aminzade Z, Azizi N, Taha S, Sadeghian N, Varghese L, Kouhanjani M, Niknam N, Babocs D, El-Assaad F, Russomano T, Murrell D, Paydar S, Bunick C, Christiansen R, Melin M. Leveraging space innovations for cancer breakthroughs on Earth. Trends In Cancer 2025, 11: 433-440. PMID: 40082142, DOI: 10.1016/j.trecan.2025.02.003.Peer-Reviewed Original ResearchConceptsTumor microenvironmentRefine treatment strategiesImproving cancer diagnosticsCancer cell behaviorInduce profound alterationsTumor biologyTreatment strategiesImmune responseCancer progressionCancer therapeuticsCancer breakthroughsCancerCancer biologyTumorCancer diagnosticsEnhance drug discoveryTherapeuticsMicrogravity-induced changes
2024
Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities
Kewan T, Stahl M, Bewersdorf J, Zeidan A. Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities. Current Hematologic Malignancy Reports 2024, 19: 138-150. PMID: 38632155, DOI: 10.1007/s11899-024-00733-y.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationAllogeneic hematopoietic stem cell transplantationLower-risk MDSErythropoiesis-stimulating agentsHypomethylating agentsIPSS-MHR-MDSRisk stratificationMolecular International Prognostic Scoring SystemRisk of leukemia progressionTreated with hypomethylating agentsInternational Prognostic Scoring SystemTreatment of myelodysplastic syndromesOral hypomethylating agentsHigh-risk MDSPrognostic scoring systemStem cell transplantationEnhanced risk stratificationRecent FindingsRecent advancesRefine treatment strategiesQuality-of-life improvementAssociated with treatmentTreatment decision-makingIntensive chemotherapyMDS patients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply